-James C Burnett Researcher Activity Profile

Research Author Detailed Information 

James C Burnett Publication Rate By Year

James C Burnett has published 2 paper(s) in 2006, 9 paper(s) in 2007, 5 paper(s) in 2008, for a total of 16 research publications in total.

James C Jc Burnett Author Information

LAST NAME: burnett

FIRST NAME: James C

INITIALS: jc

AFFILIATION:

Papers

James C Burnett's Publication Record

1. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. Year Published: 2007
SAIC-Frederick, Inc., Target Structure-Based Drug Discovery Group, Frederick, Frederick, Inc., National Cancer Institute at Frederick, P.O. Box B, F.V.C. 310, Frederick, Maryland 21702, USA.
2. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. Year Published: 2006
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55904, USA. huntley.brenda@mayo.edu
3. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Year Published: 2006
Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick Maryland, USA 21702.
4. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Year Published: 2007
Cardiorenal Research Laboratory and Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA. cataliotti.alessandro@mayo.edu
5. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Year Published: 2007
Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA. boerrigter.guido@mayo.edu
6. Impaired functional status and echocardiographic abnormalities signifying global dysfunction enhance the prognostic significance of previously unrecognized myocardial infarction detected by electrocardiography. Year Published: 2007
Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA. ammar.khawaja@mayo.edu
7. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. Year Published: 2007
Target Structure-based Drug Discovery Group, SAIC-Frederick, Inc., Frederick, Maryland 21702, USA.
8. Natriuretic peptides and myocardial structure: insights from population genetics. Year Published: 2007
9. Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Year Published: 2007
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. Costello.Lisa@mayo.edu
10. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure. Year Published: 2007
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St. SW, Gugg. 9-01, Rochester, MN 55905, USA. martin.fernando@mayo.edu
11. Prognostic markers in heart failure--congestion, neurohormones, and the cardiorenal syndrome. Year Published: 2008
Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA. jblair1@gmail.com
12. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Year Published: 2008
Mayo Cardiorenal Research Laboratory, 200 First St SW, Rochester, MN 55905. redfield.margaret@mayo.edu.
13. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Year Published: 2008
Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA.
14. Prognostic markers in heart failure--congestion, neurohormones, and the cardiorenal syndrome. Year Published: 2008
Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA. jblair1@gmail.com
15. Biology of the natriuretic peptides. Year Published: 2008
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
16. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Year Published: 2007
Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. miller.wayne@mayo.edu